Medivir Ab

Janssen R&d Ireland

Kevin Parkes

Hans Kristian Wallberg

Piaoyang Sun

Bertil Samuelsson

Tony Johnson

Ming-Hua Xu

Guo-Qiang Lin

Xin-Sheng Lei

Bart Rudolf Romanie Kesteleyn

Bengt Bertil Samuelsson

Wim Bert Griet Schepens

Genadiy Kalayanov

Johannes Wilhelmus J Thuring

Jörg Kurt Wegner

Joerg Kurt Wegner

HIV inhibitors of formula (I) wherein Ris halo, Calkoxy, trifluoromethoxy; Ris a group of formula (A); Ris a group of formula (B); Ris a group of formula (C); n is 0 or 1; A is CH or N; Rand Rare hydrogen, Callyl, halo; Rand Rare Callyl or Calkoxy-Calkyl; Ris Callyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; Ris hydrogen, Calkyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.

5-amino-4-hydroxypentoyl amides

The invention provides compounds of the formula (I)  wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).

(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD). 

(2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors

Growing community of inventors

Essex, United Kingdom

Kevin Parkes